Richter Gedeon Vegyeszeti Gyar Nyrt banner
R

Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP

Watchlist Manager
Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP
Watchlist
Price: 5 040 HUF Market Closed
Market Cap: Ft1.5T

EV/IC

1.4
Current
14%
More Expensive
vs 3-y average of 1.2

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.4
=
Enterprise Value
Ft1.7T
/
Invested Capital
Ft1.4T

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.4
=
Enterprise Value
Ft1.7T
/
Invested Capital
Ft1.4T

Valuation Scenarios

Richter Gedeon Vegyeszeti Gyar Nyrt is trading above its 3-year average

If EV/IC returns to its 3-Year Average (1.2), the stock would be worth Ft4 422.46 (12% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-12%
Maximum Upside
+23 967%
Average Upside
5 984%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.4 Ft5 040
0%
3-Year Average 1.2 Ft4 422.46
-12%
5-Year Average 1.2 Ft4 422.46
-12%
Industry Average 340.1 Ft1 212 984.36
+23 967%
Country Average 1.3 Ft4 741.89
-6%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
HU
Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP
2.2T HUF 1.4 9.4
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 8.9 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 3.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 3.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 2.9 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 2.6 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 2.7 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 1 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD -9.1 4 516.9
P/E Multiple
Earnings Growth PEG
HU
R
Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP
Average P/E: 471.9
9.4
13%
0.7
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in Hungary
Percentile
43rd
Based on 55 companies
43rd percentile
0.8
Low
0.2 — 0.5
Typical Range
0.5 — 1.4
High
1.4 —
Distribution Statistics
Hungary
Min 0.2
30th Percentile 0.5
Median 1.3
70th Percentile 1.4
Max 669.4

Richter Gedeon Vegyeszeti Gyar Nyrt
Glance View

Richter Gedeon Vegyeszeti Gyar Nyrt., popularly known as Gedeon Richter, traces its origins to 1901, when its founder, Gedeon Richter, established a modest pharmacy on the outskirts of Budapest. With a deep passion for innovation and a forward-thinking mindset, Richter transformed his small endeavor into Hungary's pioneering pharmaceutical company. Today, Gedeon Richter stands as a significant player in the global pharmaceutical industry, excelling in the research, development, manufacturing, and marketing of a wide array of medicinal products. The company's emphasis on in-house innovation and strategic collaborations has enabled it to carve a niche in the field of women's healthcare, biotechnology, and central nervous system therapies. The heart of Gedeon Richter's operations lies in its robust research and development capabilities. By investing heavily in scientific excellence, the company has developed a diversified portfolio that includes generic and specialty pharmaceuticals, as well as original research-driven products. The company generates revenue through a network that spans more than 100 countries, with a strong presence in Europe, the Commonwealth of Independent States, and the global markets at large. By keeping its manufacturing processes vertically integrated and maintaining a comprehensive distribution network, Gedeon Richter not only ensures efficiency and cost-effectiveness, but also consistently delivers quality products to both niche markets and mass consumers. This strategic focus on sustainable growth, combined with its commitment to providing innovative healthcare solutions, reflects the synergy of past legacy with future-focused aspirations.

0QFP Intrinsic Value
8 006.19 HUF
Undervaluation 37%
Intrinsic Value
Price Ft5 040
R
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett